CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7044 result(s)

Continuous Erythropoietin Receptor Activator (Mircera®) for Renal Anemia

Last Updated: February 12, 2008
Result type: Reports

Continuous erythropoietin receptor activator (CERA) is a third-generation erythropoiesis stimulating agent (ESA). CERA is used to correct anemia and maintain hemoglobin levels in patients with renal (kidney) failure. CERA is administered either once every two weeks (to correct anemia) or once per month (to maintain hemoglobin levels). This of...

  • Project Number: E0025

Duloxetine hydrochloride (Cymbalta)

Last Updated: February 8, 2008
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Duloxetine hydrochloride
Indications: Depressive, Major Disorder (MDD)

  • Brand Name: Cymbalta
  • Manufacturer: Eli Lilly Canada Inc.
  • Project Number: S0125
  • Project Status: Complete
  • Submission Type: Initial

Duloxetine hydrochloride (Cymbalta)

Last Updated: February 8, 2008
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Duloxetine hydrochloride
Indications: Pain, Neuropathic, Diabetic

  • Brand Name: Cymbalta
  • Manufacturer: Eli Lilly Canada Inc.
  • Project Number: S0126
  • Project Status: Complete
  • Submission Type: Initial

Rotigotine Transdermal Patches (Neupro®) for the Treatment of Parkinson’s Disease

Last Updated: February 4, 2008
Result type: Reports

The rotigotine transdermal patch (Neupro®) is used for symptom control in Parkinson's disease. Study results indicate that rotigotine patches are effective in reducing the symptoms of early Parkinson's disease, and in reducing “off” time in advanced Parkinson's disease. Rotigotine patches offer the potential benefits of once-daily, topic...

  • Project Number: E0056